Antiarrhythmic activity of heptacaine and some of its derivatives.
In the evaluation of experimental antiarrhythmic effect in guinea pigs, by a method of antagonizing ouabain arrhythmogenity, there was found a maximum effect of N-[2-(2-heptyloxy-phenylcarbamoyloxy)-ethyl]-piperidinium-chloride (heptacaine). The shortening or prolongation of the alkoxy substitution in the ortho-position, or the shift of hexyloxy substitution to the meta- or para-position, respectively, causes a decrease in activity. Negative chronotropic effect of heptacaine is increased and prolonged during the 5th min after acute i.v. application. The effect of lidocaine was short-lasting and decreased. In antagonizing experimental adrenaline (epinephrine) arrhythmogenity, heptacaine showed an important antiarrhythmic effect, too. In the relative hypotensive activity evaluation, there was an important effect in the 1st min after i.v. application and this decreased to the same values as those of lidocaine in the 5th min. Hypotensive effect evaluation of lidocaine and heptacaine after higher doses than therapeutic ones showed that the hypotensive effect of heptacaine takes place at the same rate as that of lidocaine and by the 10th min reaches control values. Values of experimental partition coefficient showed an increase in relation to prolongation of ortho-alkoxy substitution in the sequence: propoxy less than pentyloxy less than heptyloxy less than nonyloxy. Submaximal value by the heptacaine may reflect an optimal hydrophylic-lipophylic balance of its molecule. But in the evaluation on antiouabain effect and partition coefficient, there is no simple direct correlation in structure-activity relationship.
D000818:Animals; D000889:Anti-Arrhythmia Agents; D004077:Digoxin / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D008297:Male; D008520:Medigoxin / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship
D000889:Anti-Arrhythmia Agents; D010880:Piperidines; C013549:heptacaine; D010042:Ouabain; D004077:Digoxin; D008520:Medigoxin; D004837:Epinephrine